OCGN
NASDAQ · Biotechnology
Ocugen Inc
$1.28
+0.04 (+3.23%)
Open$1.26
Previous Close$1.24
Day High$1.30
Day Low$1.25
52W High$2.73
52W Low$0.93
Volume—
Avg Volume5.06M
Market Cap430.67M
P/E Ratio—
EPS$-0.18
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+2,241.4% upside
Current
$1.28
$1.28
Target
$29.97
$29.97
$22.68
$29.97 avg
$39.58
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.15M | 214.85M | 205.76M |
| Net Income | -79,131,278 | -16,849,465 | -19,542,916 |
| Profit Margin | -1,537.4% | -7.8% | -9.5% |
| EBITDA | -70,587,901 | -26,350,714 | -23,624,019 |
| Free Cash Flow | — | -15,177,197 | -13,829,123 |
| Rev Growth | — | +3.8% | +8.3% |
| Debt/Equity | 0.97 | 0.42 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |